Back to Journals » Drug Design, Development and Therapy » Volume 8

Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: a bioinformatic and animal study

Authors Su JH, Chang C, Xiang Q, Zhou ZW, Luo R, Yang L, He ZX, Yang HT, Li J, Bei Y, Xu JM, Zhang MJ, Zhang QH, Su ZJ, Huang YD, Pang JY, Zhou SF

Received 30 August 2014

Accepted for publication 22 September 2014

Published 12 December 2014 Volume 2014:8 Pages 2555—2602

DOI https://doi.org/10.2147/DDDT.S73476

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Wei Duan

Junhui Su,1–3,* Cui Chang,3,* Qi Xiang,1,2 Zhi-Wei Zhou,4 Rong Luo,5 Lun Yang,6 Zhi-Xu He,7 Hongtu Yang,2,3 Jianan Li,1 Yu Bei,1 Jinmei Xu,1,2 Minjing Zhang,1 Qihao Zhang,1 Zhijian Su,1 Yadong Huang,1 Jiyan Pang,5 Shu-Feng Zhou4,7

1Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, 2Department of Pharmacy, Jinan University, Guangzhou, 3The People’s Hospital of Shenzhen City, Shenzhen, People’s Republic of China; 4Department of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL, USA; 5School of Chemistry and Chemical Engineering, Sun Yat-Sen University, Guangzhou, 6Bio-X Institutes, Key Laboratory for the Genetics of Development and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, 7Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guiyang Medical University, Guiyang, People’s Republic of China

*These two authors contributed equally to this work

Abstract: Natural compounds are becoming popular for the treatment of illnesses and health promotion, but the mechanisms of action and safety profiles are often unknown. Xyloketal B (XKB) is a novel marine compound isolated from the mangrove fungus Xylaria sp., with potent antioxidative, neuroprotective, and cardioprotective effects. However, its molecular targets and effects on drug-metabolizing enzymes are unknown. This study aimed to investigate the potential molecular targets of XKB using bioinformatic approaches and to examine the effect of XKB on the expression and activity of rat cytochrome P450 3a (Cyp3a) subfamily members using midazolam as a model probe. DDI-CPI, a server that can predict drug–drug interactions via the chemical–protein interactome, was employed to predict the targets of XKB, and the Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to analyze the pathways of the predicted targets of XKB. Homology modeling was performed using the Discovery Studio program 3.1. The activity and expression of rat hepatic Cyp3a were examined after the rats were treated with XKB at 7 and 14 mg/kg for 8 consecutive days. Rat plasma concentrations of midazolam and its metabolite 1'-OH-midazolam were determined using a validated high-performance liquid chromatographic method. Bioinformatic analysis showed that there were over 324 functional proteins and 61 related signaling pathways that were potentially regulated by XKB. A molecular docking study showed that XKB bound to the active site of human cytochrome P450 3A4 and rat Cyp3a2 homology model via the formation of hydrogen bonds. The in vivo study showed that oral administration of XKB at 14 mg/kg to rats for 8 days significantly increased the area under the plasma concentration-time curve (AUC) of midazolam, with a concomitant decrease in the plasma clearance and AUC ratio of 1'-OH-midazolam over midazolam. Further, oral administration of 14 mg/kg XKB for 8 days markedly reduced the activity and expression of hepatic Cyp3a in rats. Taken together, the results show that XKB could regulate networks of molecular proteins and related signaling pathways and that XKB downregulated hepatic Cyp3a in rats. XKB might cause drug interactions through modulation of the activity and expression of Cyp3a members. More studies are warranted to confirm the mechanisms of action of XKB and to investigate the underlying mechanism for the regulating effect of XKB on Cyp3a subfamily members.

Keywords: Xyloketal B, molecular target, cytochrome P450 3A, DDI-CPI tool, DAVID, midazolam, pharmacokinetics, rat, bioinformatics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells

Pan ST, Qin Y, Zhou ZW, He ZX, Zhang X, Yang T, Yang YX, Wang D, Zhou SF, Qiu JX

Drug Design, Development and Therapy 2015, 9:5511-5551

Published Date: 5 October 2015

High-throughput sequencing of 16S rDNA amplicons characterizes bacterial composition in cerebrospinal fluid samples from patients with purulent meningitis

Liu A, Wang C, Liang Z, Zhou ZW, Wang L, Ma Q, Wang G, Zhou SF, Wang Z

Drug Design, Development and Therapy 2015, 9:4417-4429

Published Date: 7 August 2015

Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study

Niu NK, Yin JJ, Yang YX, Wang ZL, Zhou ZW, He ZX, Chen XW, Zhang XJ, Duan W, Yang TX, Zhou SF

Drug Design, Development and Therapy 2015, 9:4441-4470

Published Date: 7 August 2015

Controllable drug uptake and nongenomic response through estrogen-anchored cyclodextrin drug complex

Yin JJ, Shumyak SP, Burgess C, Zhou ZW, He ZX, Zhang XJ, Pan ST, Yang T, Duan W, Qiu JX, Zhou SF

International Journal of Nanomedicine 2015, 10:4717-4730

Published Date: 27 July 2015

Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer

Ren T, Shan J, Li M, Qing Y, Qian C, Wang G, Li Q, Lu G, Li C, Peng Y, Luo H, Zhang S, Yang Y, Cheng Y, Wang D, Zhou SF

Drug Design, Development and Therapy 2015, 9:2887-2910

Published Date: 8 June 2015

Schisandrin B inhibits cell growth and induces cellular apoptosis and autophagy in mouse hepatocytes and macrophages: implications for its hepatotoxicity

Zhang Y, Zhou ZW, Jin H, Hu C, He ZX, Yu ZL, Ko KM, Yang T, Zhang X, Pan SY, Zhou SF

Drug Design, Development and Therapy 2015, 9:2001-2027

Published Date: 9 April 2015

Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells

Pan ST, Qin Y, Zhou ZW, He ZX, Zhang X, Yang T, Yang YX, Wang D, Qiu JX, Zhou SF

Drug Design, Development and Therapy 2015, 9:1601-1626

Published Date: 16 March 2015

Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells

Zhou ZW, Li XX, He ZX, Pan ST, Yang Y, Zhang X, Chow K, Yang T, Qiu JX, Zhou Q, Tan J, Wang D, Zhou SF

Drug Design, Development and Therapy 2015, 9:1511-1554

Published Date: 12 March 2015

Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells

Wang YY, Yang YX, Zhao R, Pan ST, Zhe H, He ZX, Duan W, Zhang X, Yang TX, Qiu JX, Zhou SF

Drug Design, Development and Therapy 2015, 9:993-1026

Published Date: 17 February 2015

The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells

Li JP, Yang YX, Liu QL, Zhou ZW, Pan ST, He ZX, Zhang X, Yang T, Pan SY, Duan W, He SM, Chen XW, Qiu JX, Zhou SF

Drug Design, Development and Therapy 2015, 9:1027-1062

Published Date: 17 February 2015

Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells

Wang F, Wang Q, Zhou ZW, Yu SN, Pan ST, He ZX, Zhang X, Wang D, Yang YX, Yang T, Sun T, Li M, Qiu JX, Zhou SF

Drug Design, Development and Therapy 2015, 9:537-560

Published Date: 17 January 2015

Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells

Wang F, Li H, Yan XG, Zhou ZW, Yi ZG, He ZX, Pan ST, Yang YX, Wang ZZ, Zhang X, Yang T, Qiu JX, Zhou SF

Drug Design, Development and Therapy 2015, 9:575-601

Published Date: 17 January 2015

Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells

Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Wang NJ, Zhao RJ, Zhou SF

Drug Design, Development and Therapy 2015, 9:487-508

Published Date: 14 January 2015

Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells

Ding YH, Zhou ZW, Ha CF, Zhang XY, Pan ST, He ZX, Edelman JL, Wang D, Yang ZX, Zhang XJ, Duan W, Yang TX, Qiu JX, Zhou SF

Drug Design, Development and Therapy 2015, 9:425-464

Published Date: 9 January 2015

An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides

Cheng J, Zhou ZW, Sheng HP, He LJ, Fan XW, He ZX, Sun T, Zhang X, Zhao RJ, Gu L, Cao CH, Zhou SF

Drug Design, Development and Therapy 2015, 9:33-78

Published Date: 17 December 2014

Matrix-induced autologous chondrocyte implantation for the treatment of chondral defects of the knees in Chinese patients

Zhang ZW, Zhong X, Ji HR, Tang ZB, Bai JP, Yao MM, Hou JL, Zheng MH, Wood D, Sun JZ, Zhou SF, Liu AB

Drug Design, Development and Therapy 2014, 8:2439-2448

Published Date: 5 December 2014

Readers of this article also read:

Treatment of port wine stains with pulsed dye laser: a retrospective study of 848 cases in Shandong Province, People’s Republic of China

Shi W, Wang J, Lin Y, Geng J, Wang H, Gong Y, Liu H, Zhang F

Drug Design, Development and Therapy 2014, 8:2531-2538

Published Date: 12 December 2014

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010